Exact Mass: 778.3540544
Exact Mass Matches: 778.3540544
Found 57 metabolites which its exact mass value is equals to given mass value 778.3540544,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Dolichyl beta-D-glucuronosyl-(1->3)-beta-D-glucosyl phosphate
Vinorelbine
C45H54N4O8 (778.3941444000001)
Vinorelbine is only found in individuals that have used or taken this drug. It is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer. [Wikipedia]The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Vinorelbine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Like other vinca alkaloids, vinorelbine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis. L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CA - Vinca alkaloids and analogues C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids C1907 - Drug, Natural Product
Vinorelbine base
C45H54N4O8 (778.3941444000001)
Vinorelbine
C45H54N4O8 (778.3941444000001)
Vinorelbine is a vinca alkaloid with a norvinblastine skeleton. It has a role as an antineoplastic agent and a photosensitizing agent. It is a vinca alkaloid, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a methyl ester, an acetate ester and a ring assembly. Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990s for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug. Vinorelbine is a Vinca Alkaloid. Vinorelbine is a semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. A vinca alkaloid related to VINBLASTINE that is used as a first-line treatment for NON-SMALL CELL LUNG CANCER, or for advanced or metastatic BREAST CANCER refractory to treatment with ANTHRACYCLINES. See also: Vinorelbine Tartrate (active moiety of). L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CA - Vinca alkaloids and analogues C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C932 - Vinca Alkaloid Compound C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids A vinca alkaloid with a norvinblastine skeleton. C1907 - Drug, Natural Product
amoorinin-3-O-alpha-L-rhamnopyranosyl-(1->6)-beta-D-glucopyranoside
11alpha-acetoxy-5,14,21-trihydroxy-3beta-(tri-O-acetyl-6-deoxy-alpha-L-talopyranosyloxy)-24-nor-5beta,14beta-chol-20(22)t-ene-19,23-dioic acid-19-ethyl ester-23=>21-lactone|11alpha-Acetoxy-5,14,21-trihydroxy-3beta-(tri-O-acetyl-6-desoxy-alpha-L-talopyranosyloxy)-24-nor-5beta,14beta-chol-20(22)t-en-19,23-disaeure-19-aethylester-23=>21-lacton
benzene-1,3-dicarboxylic acid,2,2-dimethylpropane-1,3-diol,ethane-1,2-diol,2-ethyl-2-(hydroxymethyl)propane-1,3-diol,hexanedioic acid,terephthalic acid
4-[4-[4-[2-[4-[2-[4-(diethylamino)phenyl]quinazolin-4-yl]oxyphenyl]propan-2-yl]phenoxy]quinazolin-2-yl]-N,N-diethylaniline
Upadacitinib hemihydrate
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors > D000075242 - Janus Kinase Inhibitors D018501 - Antirheumatic Agents
Withalongolide H
A withanolide saponin that consists of withaferin A attached to a alpha-L-rhamnopyranosyl(1->4)-beta-D-glucopyranosyl residue via a glycosidic linkage. Isolated from the aerial parts of Physalis longifolia, it exhibits antineoplastic activity.
Methyl (1R,10S,11R,19R)-11-acetyloxy-12-ethyl-4-[(12R,13S,14S)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-13-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2(7),3,5,13-tetraene-10-carboxylate
C45H54N4O8 (778.3941444000001)
methyl (1R,9R,10S,11R,12S,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
C45H54N4O8 (778.3941444000001)
an archaeal dolichyl beta-D-glucuronosyl-(1->4)-alpha-D-glucosyl phosphate
Alocrest
C45H54N4O8 (778.3941444000001)
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01C - Plant alkaloids and other natural products > L01CA - Vinca alkaloids and analogues D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000970 - Antineoplastic Agents > D014748 - Vinca Alkaloids
[(1S,2R,4S,5R,6S,7S,8R,9R,12R)-7,12-diacetyloxy-6-(acetyloxymethyl)-5-benzoyloxy-2,10,10-trimethyl-4-octanoyloxy-11-oxatricyclo[7.2.1.01,6]dodecan-8-yl] benzoate
[6-[2,3-bis[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
[(2R,3R,6R)-6-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
[(2R,3R,6R)-6-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
[(2R,3R,6R)-6-[2,3-bis[[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy]propoxy]-3,4,5-trihydroxyoxan-2-yl]methanesulfonic acid
Angiotensin I/II (1-5) (TFA)
C32H49F3N8O11 (778.3472720000001)
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin I/II 1-5 TFA is an active mediator of renin-angiotensin system to stimulate atrial natriuretic peptide (ANP) secretion via Mas R and PI3K-Akt-NOS pathway.[1][2].
Angiotensin I/II (1-5) (TFA)
C32H49F3N8O11 (778.3472720000001)
Angiotensin I/II 1-5 TFA is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin I/II 1-5 TFA is an active mediator of renin-angiotensin system to stimulate atrial natriuretic peptide (ANP) secretion via Mas R and PI3K-Akt-NOS pathway.[1][2].